Pierre fabre to commercialize and distribute the first approved allogeneic t-cell immunotherapy in europe following transfer of the european commission marketing authorization of ebvallo™ (tabelecleucel)

Castres, france & thousand oaks, calif.--(business wire)---- $atra #cart--pierre fabre and atara biotherapeutics, inc. (nasdaq: atra) today announced the transfer of the european commission (ec) marketing authorization (ma) for ebvallo™ (tabelecleucel) for patients with relapsed or refractory epstein‑barr virus positive post‑transplant lymphoproliferative disease (ebv+ ptld) from atara to pierre fabre.
ATRA Ratings Summary
ATRA Quant Ranking